

## Effects of GSK v Teva Ripple after SCOTUS Denies Cert

May 23, 2023

### ATTORNEYS

Blau, Ross

Haroon, Gulrukh

Landmon, Chad

### PRACTICE AREAS

Intellectual Property

Patents

Chad Landmon, Ross Blau, and Gulrukh Haroon

*Life Sciences IP Review*

Axinn partner Chad Landmon and associates Ross Blau and Gulrukh Haroon co-authored the *Life Sciences IP Review* article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."

[Click here](#) to access the publication. A subscription is required.